Key result
A reduced bivalirudin bolus-only dose was associated with similar rates of in-hospital death, MI, or urgent revascularization compared to conventional dosing in elective PCI.
Why the study?
Does a reduced bivalirudin dose (bolus only) maintain efficacy and safety compared to conventional dosing (bolus plus infusion) in patients undergoing elective PCI?
Observational (n=397)
Does a reduced bivalirudin dose (bolus only) maintain efficacy and safety compared to conventional dosing (bolus plus infusion) in patients undergoing elective PCI?
A bolus-only dose of bivalirudin may be as effective and safe as the conventional bolus-plus-infusion regimen for patients undergoing elective PCI, potentially reducing costs.
Answers are grounded in this paper and cite their sources.
Should not yet alter bivalirudin dosing in elective PCI; leaves open need for randomized confirmation of bolus-only efficacy.
BACKGROUND: Anticoagulation therapy during percutaneous coronary intervention (PCI) has been the focus of numerous clinical trials. Low-anticoagulant doses have been successfully used in patients undergoing elective PCI, a situation with low-thrombogenic milieu. OBJECTIVE: The purpose of the study was to evaluate the safety and efficacy of shorter duration of treatment with bivalirudin in patients undergoing elective PCI and receiving optimal antiplatelet therapy. METHODS: We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0.75 + 1.75 mg/kg per h for the duration of PCI; n = 197) or a reduced bivalirudin dose (IV bolus of 0.75 mg/kg; n = 200). RESULTS: Procedural success was obtained in 100% of cases. The primary end point (in-hospital death, acute myocardial infarction, or need for urgent target vessel revascularization) did not differ between both the groups (6 patients [3%] in the conventional dose group vs 5 patients [2.5%] in the reduced dose group). Major bleeding occurred in 1 patient in the conventional dose group (P = nonsignificant [NS]). Minor bleeding occurred in 4 patients (2%) in the conventional dose group vs 5 patients (2.5%) in the reduced dose group (P = NS) and was mainly due to bleeding at entry site. CONCLUSION: In patients undergoing elective PCI, using bivalirudin as a bolus only dosing may be as effective and less costly when compared with bolus followed by an infusion for the duration of the intervention. A larger study is needed to confirm our findings.
No takes yet. Share an insight, caveat, or question.
Sheikh‐Taha et al. (2012) conducted an observational in Elective percutaneous coronary intervention (n=397). Reduced bivalirudin dose vs. Conventional bivalirudin dosing (IV bolus of 0.75 + 1.75 mg/kg per h) was evaluated on in-hospital death, acute myocardial infarction, or need for urgent target vessel revascularization (p=NS). A reduced bivalirudin bolus-only dose was associated with similar rates of in-hospital death, MI, or urgent revascularization compared to conventional dosing in elective PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: